To find out about our initiatives at the EU level, upcoming events and campaigns :
This paper outlines recommendations to EU institutions, national governments and relevant groups in Europe concerning the COVID-19 response and recovery plans with regard to chronic diseases. The lessons from this crisis must be learnt. The below proposals aim to support reflections on preparedness for potential future pandemics or other crises, which may occur as a result of factors like climate change; but also to reinforce healthcare systems’ capacity to achieve long-term public health objectives.
European Parliament Interest Group on Allergy and Asthma
Read more about the Interest Group Activities here.
EAACI maintains strong collaborations with:
 |
European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) to advocate better patient care |
 |
European Chronic Disease Alliance (ECDA) to raise awareness among policy makers about the surge in chronic diseases |
 |
Alliance for Biomedical Research in Europe (BioMed Alliance) to promote excellence and innovation in European biomedical research |
 |
European Medicines Agency (EMA) to support safe and effective quality interventions for allergic diseases and asthma |
The European Strategic Forum on Allergic Diseases
The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
Read the full manuscript here.
EAACI Campaigns
United Action for Allergy and Asthma – a European political Call to Action
The European Parliament Interest Group, EAACI and EFA launched the European political Call to Action “United Action for Allergy and Asthma” in April 2017 during a policy event in the European Parliament (Brussels). The Call to Action was promoted via a pan-European advocacy campaign uniting all strategic European and national stakeholders as well as interested individuals to help drive action and policy responses to allergy and asthma, in support of patients’ rights.
In only five months, the campaign secured broad endorsement and received ample coverage in the European press. It was supported by nearly 190 national and European organisations, more than 5,000 individuals from across Europe and over 32 policy-makers.
European Parliament 115/2016 Written Declaration on Chronic Respiratory Diseases
With the support of EFA, EAACI and 7 other European health and respiratory organisations, 12 members of the Interest Group and colleagues tabled a written declaration on Chronic Respiratory Diseases in the European Parliament in autumn 2016, calling on the European Council and the European Commission to act for better prevention, diagnosis, care and rehabilitation in Chronic Respiratory Diseases. The Declaration was supported by over 250 Members of the European Parliament from 26 EU countries.
EAACI Advocacy Manifesto
The EAACI European Advocacy Manifesto proposes a series of evidence-based recommendations to tackle the burden of allergy in Europe, foster allergy research and help strengthen Allergology as a medical specialty. The European Commission and Parliament have a duty to act to help millions of European citizens and relieve their suffering from allergies.
Anaphylaxis is an allergic reaction that can be severe and potentially life threating. So be ready to react on time, and learn and teach others how to use your adrenaline pen. It can save your life... Learn to recognise the symptoms and the triggers. Implement them in your daily life to improving your quality of life. And remember, if you are not sure about some food, just do not eat it!
EAACI launched its Food Allergy Campaign in 2012 to raise awareness of the sharp increase of anaphylaxis in children. It aimed at educating the public to recognise the symptoms and its triggers, and to teach methods of how to react in case of emergency, e.g. by using an adrenaline pen.
-
Food Allergy and Anaphylaxis Public Declaration, launched during the Food Allergy and Anaphylaxis Meting, FAAM 2013, in Nice, France. Also available in Dutch, French, German, Italian and Spanish.
To read the press release "EAACI issues European Food Allergy & Anaphylaxis Public Declaration", please click here.
Food Allergy and Anaphylaxis Guidelines
The Food Allergy Campaign was supported by the EAACI Patients Organisations Committee, with more than 25 country representatives from across Europe, North America, South America, the Middle East, Asia and Oceania.
EAACI Summit on allergen Immunotherapy
In February 2011, the EAACI Summit on allergen immunotherapy took place in Geneva, gathering some experts in the field and other stakeholders such as patient representatives, regulators and allergen manufacturers. The current status of different issues regarding immunotherapy was discussed, assessing certainties and controversies, identifying niches for further research, while established knowledge was set “black on white”.
100 Years of Allergen Immunotherapy EAACI Celebration: review of Unanswered questions
The resulting output of the EAACI Summit on allergen immunotherapy, the document “One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions”, was published in Allergy. Read it here.
A European Declaration on Immunotherapy
EAACI prepared a pivotal document: A ‘European Declaration on Immunotherapy’, which was co-signed by EFA, the European Federation of Allergy and Airway Diseases Patient Associations, and GA2LEN, an EU-supported Network of Excellence. The aim was to provide a robust statement on the use of immunotherapy, its availability for allergic patients, and the need for resources to fund research, among other points. It was signed by national and supranational allergy societies, patient organizations, allergen manufacturers and other third parties. Read it here.